ECOG E2100 - Cancer Therapy Evaluation Program (CTEP)
ECOG E2100 - Cancer Therapy Evaluation Program (CTEP) ECOG E2100 - Cancer Therapy Evaluation Program (CTEP)
VEGF -2578 AA & -1154 AA genotypes in combination arm Median OS Control arm=25.2 mo Combination arm=26.7 mo Combination arm AA=37.0 mo outperformed control p=0.035 46.5 mo 25.2 mo 25.2 mo 37.0 mo Median OS Control arm=25.2 mo Combination arm=26.7 mo Combination arm AA=46.5 mo p=0.047
Genetic variability of VEGF predicts clinically significant hypertension in E2100 SNP % Grade 3/4 hypertension (#/%) by genotype VEGF-634 CC=0% (n=27;15.3%) vs. GC=22% (n=82; 46.3%) vs. GG=19% (n=68; 38.4%) p-value 0.013 CC vs. GC+GG 0.005 VEGF-1498 TT=8% (n=60; 33.9%) vs. CT=22% (n=82; 46.3%) vs. CC=23% (n=35; 19.8%) 0.056 TT vs. CC+CT 0.022 Schneider et al; SABCS, 2007
- Page 1 and 2: ECOG Pharmacogenomics: Anti-Angioge
- Page 3 and 4: Genetic variability impacts angioge
- Page 5 and 6: Bevacizumab in breast cancer-E2100:
- Page 7 and 8: PFS Proportion 1.0 0.8 0.6 0.4 0.2
- Page 9 and 10: GOOD NEWS=all subgroups gained bene
- Page 11 and 12: Germline genetic variation in tumor
- Page 13 and 14: Candidate SNPs meet fundamental •
- Page 15 and 16: Genetic variability in tumor angiog
- Page 17: VEGF -2578 AA & -1154 AA genotypes
- Page 21 and 22: VEGF genotypes may be associated wi
- Page 23 and 24: VEGF Promoter & 5’-UTR Re-sequenc
- Page 25 and 26: Caucasians African-Americans 76% 70
- Page 27 and 28: Acknowledgements • David Flockhar
VEGF -2578 AA & -1154 AA<br />
genotypes in combination arm<br />
Median OS<br />
Control arm=25.2 mo<br />
Combination arm=26.7 mo<br />
Combination arm AA=37.0 mo<br />
outperformed control<br />
p=0.035 46.5 mo<br />
25.2 mo<br />
25.2 mo<br />
37.0 mo<br />
Median OS<br />
Control arm=25.2 mo<br />
Combination arm=26.7 mo<br />
Combination arm AA=46.5 mo<br />
p=0.047
Change language